289,117 Shares in Health Catalyst, Inc. (NASDAQ:HCAT) Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 289,117 shares of the company’s stock, valued at approximately $2,044,000. Raymond James Financial Inc. owned 0.48% of Health Catalyst at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of HCAT. Impax Asset Management Group plc lifted its stake in Health Catalyst by 7.7% in the 4th quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock valued at $19,442,000 after buying an additional 195,525 shares in the last quarter. Martin & Co. Inc. TN grew its stake in Health Catalyst by 80.0% during the fourth quarter. Martin & Co. Inc. TN now owns 490,998 shares of the company’s stock worth $3,471,000 after buying an additional 218,293 shares during the period. Legato Capital Management LLC raised its position in Health Catalyst by 3.7% in the fourth quarter. Legato Capital Management LLC now owns 87,992 shares of the company’s stock valued at $622,000 after purchasing an additional 3,171 shares during the period. Stoneridge Investment Partners LLC acquired a new position in Health Catalyst during the 4th quarter worth approximately $77,000. Finally, Dynamic Advisor Solutions LLC purchased a new position in shares of Health Catalyst in the fourth quarter valued at $180,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Health Catalyst Price Performance

Shares of NASDAQ HCAT opened at $4.55 on Monday. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm has a market cap of $319.46 million, a PE ratio of -3.37 and a beta of 1.41. The company has a fifty day moving average price of $5.03 and a 200 day moving average price of $6.85. Health Catalyst, Inc. has a 1-year low of $3.76 and a 1-year high of $9.24.

Insider Activity at Health Catalyst

In related news, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $7.51, for a total value of $39,119.59. Following the transaction, the chief operating officer now directly owns 91,253 shares in the company, valued at approximately $685,310.03. This represents a 5.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Linda Llewelyn sold 6,441 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $5.43, for a total value of $34,974.63. Following the transaction, the insider now owns 85,819 shares in the company, valued at approximately $465,997.17. This trade represents a 6.98 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 56,530 shares of company stock valued at $299,572. 2.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on HCAT. Wells Fargo & Company decreased their price target on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research note on Tuesday, January 21st. Citigroup decreased their target price on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a research report on Friday, January 10th. Stephens dropped their price target on shares of Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 6th. Piper Sandler cut their price objective on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 11th. Finally, Royal Bank of Canada decreased their price target on shares of Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 27th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.27.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.